CL2021001123A1 - Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. - Google Patents

Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.

Info

Publication number
CL2021001123A1
CL2021001123A1 CL2021001123A CL2021001123A CL2021001123A1 CL 2021001123 A1 CL2021001123 A1 CL 2021001123A1 CL 2021001123 A CL2021001123 A CL 2021001123A CL 2021001123 A CL2021001123 A CL 2021001123A CL 2021001123 A1 CL2021001123 A1 CL 2021001123A1
Authority
CL
Chile
Prior art keywords
arylsulfonylpyrrolecarboxamide
derivatives
potassium channel
channel activators
compounds
Prior art date
Application number
CL2021001123A
Other languages
English (en)
Inventor
Lars Kyhn Rasmussen
Anette Graven Sams
Wanwan Yu
Paul Robert Fleming
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2021001123A1 publication Critical patent/CL2021001123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona compuestos novedosos que activan los canales de potasio Kv3. Los compuestos tienen la estructura Aspectos separados de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y el uso de los compuestos para tratar trastornos que responden a la activación de los canales de potasio Kv3.
CL2021001123A 2018-10-30 2021-04-29 Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3. CL2021001123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201800787 2018-10-30

Publications (1)

Publication Number Publication Date
CL2021001123A1 true CL2021001123A1 (es) 2021-10-22

Family

ID=70327875

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001123A CL2021001123A1 (es) 2018-10-30 2021-04-29 Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.

Country Status (23)

Country Link
US (1) US20200131156A1 (es)
EP (1) EP3873891A1 (es)
JP (1) JP2022509416A (es)
KR (1) KR20210086661A (es)
CN (1) CN113056461A (es)
AR (1) AR116898A1 (es)
AU (1) AU2019373367A1 (es)
BR (1) BR112020013011A2 (es)
CA (1) CA3116273A1 (es)
CL (1) CL2021001123A1 (es)
CO (1) CO2021005579A2 (es)
CR (1) CR20210285A (es)
DO (1) DOP2021000081A (es)
EA (1) EA202190899A1 (es)
EC (1) ECSP21038534A (es)
IL (1) IL282639A (es)
JO (1) JOP20210091A1 (es)
MA (1) MA54061A (es)
MX (1) MX2021004935A (es)
PE (1) PE20211975A1 (es)
SG (1) SG11202104348XA (es)
TW (1) TW202031645A (es)
WO (1) WO2020089262A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023017263A1 (en) 2021-08-10 2023-02-16 Autifony Therapeutics Limited Potassium channel modulators
WO2024121552A1 (en) 2022-12-06 2024-06-13 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100179203A1 (en) * 2007-07-04 2010-07-15 Antonio Nardi Novel pyrazole derivatives useful as potassium channel modulators
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
WO2011073276A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
WO2011073269A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Piperidine aryl sulfonamide derivatives as kv1.3 modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
FR2967674B1 (fr) * 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
WO2013120104A2 (en) * 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9422252B2 (en) * 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
GB201521751D0 (en) * 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
EP3873891A1 (en) 2021-09-08
ECSP21038534A (es) 2021-06-30
WO2020089262A1 (en) 2020-05-07
CA3116273A1 (en) 2020-05-07
PE20211975A1 (es) 2021-10-05
JOP20210091A1 (ar) 2023-01-30
TW202031645A (zh) 2020-09-01
SG11202104348XA (en) 2021-05-28
CN113056461A (zh) 2021-06-29
IL282639A (en) 2021-06-30
CO2021005579A2 (es) 2021-05-10
AR116898A1 (es) 2021-06-23
KR20210086661A (ko) 2021-07-08
DOP2021000081A (es) 2021-07-30
CR20210285A (es) 2021-09-16
AU2019373367A1 (en) 2021-05-27
MA54061A (fr) 2021-12-15
JP2022509416A (ja) 2022-01-20
EA202190899A1 (ru) 2021-08-19
MX2021004935A (es) 2021-06-08
BR112020013011A2 (pt) 2021-05-04
US20200131156A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
CO2018008707A2 (es) Inhibidores de la proteína quinasa 1 que interactúa con el receptor
DOP2017000298A (es) Reguladores de nrf2
CL2017001124A1 (es) Agentes inmunomoduladores
BR112018006259A2 (pt) "adjunto compressível com estruturas de suporte intermediárias"
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2019001736A1 (es) Polimorfos.
CL2015002083A1 (es) Composiciones herbicidas sinergicas
CL2019003430A1 (es) Tratamiento conjunto antineoplásico.
CL2019001737A1 (es) Polimorfos.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2018001837A1 (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CL2021001123A1 (es) Derivados de arilsulfonilpirrolcarboxamida como activadores de canales de potasio kv3.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7